NEW YORK, Feb. 1, 2017 /PRNewswire/ -- Connecting Patients and CaregiversFor self-administration, adherence with drug therapy and disease management protocols has become a primary concern within the healthcare and pharmaceutical industries. For chronic conditions adherence has a direct effect on the patient's quality-of-life. Wirelessly enabled devices – drug injection devices that are designed to address the patient adherence issue by reminding and recording data about patient dosing activity and making it available to HCPs – are gaining interest among industry and managed care participants. Efforts to enhance adherence have a non-negligible effect on drug formulations and delivery decisions, and are a significant factor in the prescribing decisions of most physicians. The connected device ecosystem includes OEM device suppliers, drug developers, human factors consultants and aftermarket third-party devices.Market-driven Product StrategiesA longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumercompatible form of packaging and application.'Much of the activity surrounding connected drug injection devices is focused on chronic diseases – conditions where the ability of caregivers to access data on patient self-administration activities, patient reported outcomes, and feedback on the user experience can yield significant benefits in patient Quality of Life.'What You Will Learn• What drug injection devices incorporate wireless connectivity technology, how do they work and what new capabilities do they offer to patients and their HCPs?• What benefits do wirelessly enabled drug injectors provide to patients in the area of improved adherence? Patient reported outcomes? HCP/patient communication?• What therapeutic areas are the current focus of wirelessly enabled devices?• Who are the companies behind the growth of wirelessly enabled injection devices? What are their development activities and corporate alliances and affiliations• What is the importance of pharma-device alliances and design partnerships on wirelessly enabled drug injection device commercialization and market access?• What does the current market for wirelessly enabled drug injection devices look like? What will it look like in 2022?• What are the key market drivers for the growth of wirelessly enabled injection devices?Who Should Read this ReportDevelopment• Drug Developers• Device Suppliers• CMOs• Components/APIs• Testing/Validation• Clinical Trial MgmtIndustry• Pharma Managers• Biotech Managers• Drug Marketers• Industry Strategists• Financial Analysts• Management ConsultantsMarket• Clinical Managers• Drug Distributors• Pharma Regulators• FDA Consultants• Managed Care ManagersRead the full report: http://www.reportlinker.com/p04665928-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com
__________________________Contact Clare: [email protected] US: (339)-368-6001Intl: +1 339-368-6001
Advertisement
__________________________Contact Clare: [email protected] US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wirelessly-enabled-injection-devices-to-2022-300400764.html
SOURCE Reportlinker
